Fenwick Represents Third Harmonic Bio in its $213.1 Million Upsized Initial Public Offering

By: Effie Toshav, Robert A. Freedman, Ryan Mitteness, Joshua W. Damm, Adam Conway, Frances Fuqua, Tempestt Edward, Marshall Mort, Christophe Delrieu, Bryan Belok, William R. Skinner, Alexis M. Maguina

Fenwick represented Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company developing a potent, highly selective, oral KIT inhibitor for the treatment of severe inflammatory diseases, in its initial public offering of 12,535,000 shares of common stock, including the full exercise of the underwriters’ option to purchase up to an additional 1,635,000 shares of common stock, at a public offering price of $17.00 per share. The total offering price was $213.1 million and the shares began trading on September 15, 2022 on the Nasdaq Global Market.

Morgan Stanley, Jefferies and Cowen acted as joint book-running managers for the offering. LifeSci Capital acted as co-manager for the offering. More information can be obtained from the company’s announcement.

The Fenwick transaction team included corporate partners Effie Toshav, Robert Freedman and Ryan Mitteness, and associates Joshua Damm, Adam Conway, Frances Fuqua and Tempestt Edward; executive compensation and employee benefits partner Marshall Mort and associates Christophe Delrieu and Bryan Belok; and tax partner William Skinner and associate Alexis Maguina.

Login

Don’t have an account yet?

Register